Flagship Biosciences is a digital pathology services company created by industry leading molecular pathologists to fill the growing need for advanced digital technology in drug development and medical devices. Our pathologists deliver quantitative results so our customers can make efficacy and toxicology assessments faster. Our fast growing client list ranges from the largest pharmaceutical and medical device companies to small virtual biotechs. Flagship Biosciences LLC was founded in 2009 by David Young DVM DACVP DABT and Frank Voelker DVM DACVP MS, two experienced pharmaceutical pathologists who together saw the need for high quality application of digital pathology technology. The company recently moved from Boulder, Colorado to Flagstaff, Arizona, to take advantage of an attractive economic climate in a university town, with the advantages offered by NACET for highly secure laboratory and data center

Flagship Biosciences was created by industry leading molecular pathologists to fill the growing need for companion diagnostics and quantitative pathology in drug development and medical devices. Our focus is tissue analysis, delivered by experts in MD and veterinary pathology, image analysis, cancer biology, and diagnostics regulatory.

We provide full service pathomolecular services, from study design and tissue procurement through histology/IHC to pathology and image analysis results.

Our services include:

-Develop histology and IHC biomarkers
-Quantitate efficacy and toxicity tissue assays
-Increase visibility between study sponsors and their CROs
-Facilitate partnerships in clinical development
-Multiplexed fluorescent assays
-Angiogenesis evaluations
-Precliinical diabetes efficacy evaluation
-Ophthalmology angiogenesis assays
-Solid tumor IHC
-Hematopathology quantiative assays

专注领域

histopathology services, digital pathology services, image analysis, IHC quantitation, tissue biomarker analysis, companion diagnostics, tissue microarray analysis